These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26433816)

  • 1. Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?
    Wong HH; Halford S
    Lancet Oncol; 2015 Oct; 16(13):1287-8. PubMed ID: 26433816
    [No Abstract]   [Full Text] [Related]  

  • 2. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Building firm foundations for therapy development.
    Dignam JJ; Karrison TG
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25710961
    [No Abstract]   [Full Text] [Related]  

  • 4. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A statistical evaluation of dose expansion cohorts in phase I clinical trials.
    Boonstra PS; Shen J; Taylor JM; Braun TM; Griffith KA; Daignault S; Kalemkerian GP; Lawrence TS; Schipper MJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25710960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
    Wages NA; Tait C
    J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose selection in phase I studies: why we should always go for the most effective.
    Haines IE
    J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose selection in phase I studies: why we should always go for the top.
    Sleijfer S; Wiemer E
    J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
    [No Abstract]   [Full Text] [Related]  

  • 11. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial design in cancer drug development.
    Eisenhauer EA; O'Dwyer PJ; Christian M; Humphrey JS
    J Clin Oncol; 2000 Feb; 18(3):684-92. PubMed ID: 10653884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early phase cancer clinical trials: design, ethics and future directions.
    Coupe N; Gupta A; Lord SR
    Br J Hosp Med (Lond); 2015 Jul; 76(7):409-13. PubMed ID: 26140560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some notable properties of the standard oncology Phase I design.
    Hather GJ; Mackey H
    J Biopharm Stat; 2009; 19(3):543-55. PubMed ID: 19384695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-dimensional search algorithm for dose-finding trials of two agents.
    Lee BL; Fan SK
    J Biopharm Stat; 2012; 22(4):802-18. PubMed ID: 22651116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New adaptive method for phase I trials in oncology.
    Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
    Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose finding with longitudinal data: simpler models, richer outcomes.
    Paoletti X; Doussau A; Ezzalfani M; Rizzo E; Thiébaut R
    Stat Med; 2015 Sep; 34(22):2983-98. PubMed ID: 26109523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.